1-3 of 3
Philip A. Pancari, MD
Close
Sort by
Journal Articles

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Raji Shameem, MD, Philip A. Pancari, MD, Henry Fung, MD, Lianchun Xiao, PhD, Xuelin Huang, PhD, Woonbok Chung, PhD, Hagop M. Kantarjian, MD, Jean-Pierre J. Issa, MD
Journal: Blood
Blood (2016) 128 (22): 3170.
https://doi.org/10.1182/blood.V128.22.3170.3170
Published: 2016
Journal Articles

Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Philip A. Pancari, MD, Henry Fung, Hagop M. Kantarjian, MD, Lianchun Xiao, Huang Xuelin, Jean-Pierre Issa, MD
Journal: Blood
Blood (2015) 126 (23): 3775.
https://doi.org/10.1182/blood.V126.23.3775.3775
Published: 2015
Journal Articles

A Proposed Steroid Mobilization Test to Separate Margination From Marrow Suppression and to Determine Drug Cessation for Safety in Lenalidomide-Induced Neutropenia in Non-Del(5q) MDS Low and INT-1 Patients

Philip A. Pancari, MD, Emmanuel C. Besa, MD, Jackie Quan, Amanda Padula, Erev E. Tubb, MD, Raymond Vvacqua
Journal: Blood
Blood (2012) 120 (21): 4942.
https://doi.org/10.1182/blood.V120.21.4942.4942
Published: 2012